wave life sciences inc - WVE
WVE
Close Chg Chg %
3.16 -0.03 -0.79%
Closed Market
3.13
-0.03 (0.79%)
Volume: 2.66M
Last Updated:
Nov 13, 2026, 4:00 PM EDT
Company Overview: wave life sciences inc - WVE
WVE Key Data
| Open $3.12 | Day Range 3.00 - 3.20 |
| 52 Week Range 3.00 - 21.73 | Market Cap $674.52M |
| Shares Outstanding 197.23M | Public Float 165.32M |
| Beta -1.41 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.07 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.98M |
WVE Performance
| 1 Week | -6.98% | ||
| 1 Month | 0.00% | ||
| 3 Months | -42.14% | ||
| 1 Year | -55.79% | ||
| 5 Years | -32.83% |
WVE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
21
Full Ratings ➔
About wave life sciences inc - WVE
Wave Life Sciences, Inc. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It develops and commercializes a pipeline of RNA medicines across a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.
WVE At a Glance
Wave Life Sciences, Inc.
733 Concord Avenue
Cambridge, Massachusetts 02138
| Phone | N/A | Revenue | 42.73M | |
| Industry | Biotechnology | Net Income | -204,378,000.00 | |
| Sector | Health Technology | Employees | 317 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
WVE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 67.102 |
| Price to Book Ratio | 6.154 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.091 |
| Enterprise Value to Sales | 53.611 |
| Total Debt to Enterprise Value | 0.008 |
WVE Efficiency
| Revenue/Employee | 134,785.489 |
| Income Per Employee | -644,725.552 |
| Receivables Turnover | 33.485 |
| Total Asset Turnover | 0.086 |
WVE Liquidity
| Current Ratio | 6.467 |
| Quick Ratio | 6.467 |
| Cash Ratio | 6.333 |
WVE Profitability
| Gross Margin | 79.282 |
| Operating Margin | -504.091 |
| Pretax Margin | -478.335 |
| Net Margin | -478.335 |
| Return on Assets | -41.259 |
| Return on Equity | -54.968 |
| Return on Total Capital | -37.57 |
| Return on Invested Capital | -53.031 |
WVE Capital Structure
| Total Debt to Total Equity | 3.376 |
| Total Debt to Total Capital | 3.266 |
| Total Debt to Total Assets | 2.782 |
| Long-Term Debt to Equity | 1.814 |
| Long-Term Debt to Total Capital | 1.729 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Wave Life Sciences Inc - WVE
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 3.65M | 113.31M | 108.30M | 42.73M | |
Sales Growth
| -91.09% | +3,005.10% | -4.42% | -60.55% | |
Cost of Goods Sold (COGS) incl D&A
| 10.11M | 9.21M | 8.66M | 8.85M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 10.11M | 9.21M | 8.66M | 8.85M | |
Depreciation
| 10.11M | 9.21M | 8.66M | 8.85M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | -8.98% | -5.90% | +2.18% | |
Gross Income
| (6.47M) | 104.10M | 99.64M | 33.88M | |
Gross Income Growth
| - | +1,710.19% | -4.28% | -66.00% | |
Gross Profit Margin
| -177.17% | +91.88% | +92.00% | +79.28% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 156.26M | 172.10M | 210.04M | 249.26M | |
Research & Development
| 115.86M | 130.01M | 159.68M | 182.78M | |
Other SG&A
| 40.40M | 42.09M | 50.36M | 66.48M | |
SGA Growth
| -1.20% | +10.14% | +22.05% | +18.67% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (162.72M) | (68.00M) | (110.40M) | (215.38M) | |
Non Operating Income/Expense
| 1.58M | 9.81M | 13.40M | 11.01M | |
Non-Operating Interest Income
| 1.57M | 7.93M | 10.16M | 10.48M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (161.14M) | (58.19M) | (97.01M) | (204.38M) | |
Pretax Income Growth
| -31.60% | +63.89% | -66.71% | -110.68% | |
Pretax Margin
| -4,416.06% | -51.36% | -89.57% | -478.33% | |
Income Tax
| - | - | 681.00K | (677.00K) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | 681.00K | (677.00K) | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (161.82M) | (57.51M) | (97.01M) | (204.38M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (161.82M) | (57.51M) | (97.01M) | (204.38M) | |
Net Income Growth
| -32.38% | +64.46% | -68.67% | -110.68% | |
Net Margin Growth
| -4,434.72% | -50.76% | -89.57% | -478.33% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (161.82M) | (57.51M) | (97.01M) | (204.38M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (161.82M) | (57.51M) | (97.01M) | (204.38M) | |
EPS (Basic)
| -2.0521 | -0.5421 | -0.7015 | -1.2119 | |
EPS (Basic) Growth
| +13.00% | +73.58% | -29.40% | -72.76% | |
Basic Shares Outstanding
| 78.86M | 106.10M | 138.28M | 168.65M | |
EPS (Diluted)
| -2.0521 | -0.5421 | -0.7015 | -1.2119 | |
EPS (Diluted) Growth
| +13.00% | +73.58% | -29.40% | -72.76% | |
Diluted Shares Outstanding
| 78.86M | 106.10M | 138.28M | 168.65M | |
EBITDA
| (152.61M) | (58.79M) | (101.74M) | (206.53M) | |
EBITDA Growth
| -30.23% | +61.48% | -73.06% | -103.00% | |
EBITDA Margin
| -4,182.13% | -51.89% | -93.94% | -483.37% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 18.072 | |
| Number of Ratings | 21 | Current Quarters Estimate | -0.324 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -1.107 | |
| Last Quarter’s Earnings | -0.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.21 | Next Fiscal Year Estimate | -1.292 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 18 | 10 | 18 | 17 |
| Mean Estimate | -0.32 | -0.34 | -1.11 | -1.29 |
| High Estimates | -0.28 | -0.26 | -1.06 | -1.04 |
| Low Estimate | -0.39 | -0.41 | -1.24 | -1.71 |
| Coefficient of Variance | -8.50 | -13.80 | -3.70 | -17.09 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 19 | 20 | 16 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Wave Life Sciences Inc - WVE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Wave Life Sciences Inc - WVE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 28, 2026 | RA Capital Management LP Director | 39,515 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 28, 2026 | RA Capital Management LP Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Christian O. Henry Director | 23,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Christian O. Henry Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Mark H. N. Corrigan Director | 39,515 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Mark H. N. Corrigan Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Adrian Rawcliffe Director | 10,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Adrian Rawcliffe Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Gregory L. Verdine Director | 200,917 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Gregory L. Verdine Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Heidi L. Wagner Director | 55,630 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Heidi L. Wagner Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Ken Takanashi Director | 30,779 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Ken Takanashi Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Aik Na Tan Director | 35,668 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 8, 2026 | Aik Na Tan Director | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |